To include your compound in the COVID-19 Resource Center, submit it here.

Sanofi sets MS submission goals for Principia-partnered Btk inhibitor, details Phase II data

Two months after Sanofi announced plans to send its oral multiple sclerosis therapy into Phase III testing, the company unveiled the detailed Phase IIb data from recurring MS patients driving the Btk inhibitor’s clinical advancement.

On a conference call Thursday, Sanofi (Euronext:SAN; NASDAQ:SNY) also revealed marketing application milestones: a 2024 submission for relapsing MS and 2025 submissions for primary progressing MS

Read the full 614 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE